Nexsen (ASX:NXN) strengthens Advisory Board with global healthcare executive
Nexsen has appointed Dr Kenneth Tsang, Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong, to its Advisory Board.
Dr Tsang's appointment adds large scale healthcare operating experience to the Company as it progresses from product development and validation towards market readiness.
The appointment follows Nexsen's recently announced Memorandum of Understanding with IHH Healthcare’s Gleneagles Hospital Hong Kong and forms part of the Company's broader strategy to build clinical and commercial pathways for its proprietary rapid diagnostics platform across Asia Pacific.
Highlights
Appointed Dr Kenneth Tsang to the Advisory Board.
Dr Tsang is Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong.
IHH Healthcare has a market capitalisation of approximately $25.7 billion and a network of 190 healthcare facilities across 10 countries, including 89 hospitals.
Appointment adds expertise across hospital operations, clinical services, medical affairs, procurement, supply chain and healthcare adoption pathways.
Appointment follows Nexsen's recently announced Memorandum of Understanding with Gleneagles Hospital Hong Kong, supporting the validation and potential rollout of Nexsen's proprietary rapid diagnostics platform.
Dr Tsang is a senior healthcare executive with leadership experience across one of Asia's most significant private healthcare platforms, IHH Healthcare.
He currently serves as Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong, part of IHH Healthcare, one of the world's largest private healthcare providers with a market capitalisation of approximately $25.7 billion and a network of 190 healthcare facilities across 10 countries, including 89 hospitals.
He has served as Chief Executive Officer of Gleneagles Hospital Hong Kong since January 2021 and was appointed Chief Executive Officer of IHH Healthcare North Asia in April 2024.
Dr Tsang's appointment adds large scale healthcare operating experience to Nexsen at a key stage in the Company's development, as it progresses from product development and validation towards market readiness.
His experience spans hospital operations, clinical service delivery, medical affairs, quality systems, risk management, specialist clinic development, procurement and healthcare adoption pathways.
This expertise is expected to support Nexsen across product rollout planning, clinical workflow integration, supply chain readiness and regional market engagement across Asia Pacific.
The appointment follows Nexsen's recently announced Memorandum of Understanding with Gleneagles Hospital Hong Kong, part of IHH Healthcare, supporting the validation and potential rollout of Nexsen's proprietary rapid diagnostics platform.
The Company stated the Memorandum of Understanding represents its first Asian hospital partnership and forms part of its broader strategy to build clinical and commercial pathways for its rapid diagnostics platform across the region.
As Dr Tsang said,
"I am pleased to join Nexsen's Advisory Board at an exciting stage in the Company's development. Nexsen is addressing an important healthcare need by giving clinicians faster access to reliable diagnostic information at the point of care. I look forward to supporting the Company advance its rapid diagnostics platform."
Nexsen is developing a suite of rapid point of care diagnostics for conditions that have traditionally depended on delayed laboratory testing.
The Company is focused on areas of significant unmet clinical need, where faster diagnosis can improve patient outcomes and reduce pressure on healthcare systems.
Nexsen's lead diagnostic is the GBS Rapid Sensor, a rapid point of care diagnostic for detecting Group B Streptococcus.
The Company is also developing rapid kidney function diagnostics for Acute Kidney Injury and Chronic Kidney Disease, two conditions that affect more than 850 million people globally and remain underserved by slow, lab based diagnostics, with further diagnostics in development across human health, ag tech and biosecurity.